BioConference Live for the Life Science and Biotech Community

2-3 June 2010.
BioConference Live is an information break through and the first of its kind online-only conference for the life sciences and laboratory science community. This FREE event will feature live video keynote presentations from life science thought leaders where attendees can have their question answered by presenters in real time.

In addition, BioConference Live will feature a virtual exhibit hall, track sessions and case studies, and poster sessions where researchers present and discuss their latest work.

Topics Include:

  • Chemistry
  • Biotechnology
  • Cancer Research
  • Cellular Biology
  • Drug Discovery
  • Genetics
  • Immunology
  • Lab Automation
  • Medicine
  • Molecular Biology
  • Neuroscience
  • Venture Capital

Register and participate in over 50 Live keynote and track presentations from speakers such as Dr. David Wolf M.D. NASA Astronaut and Medical Doctor, Steven Burrill CEO of Burrill & Company, Kevin Hrusovsky M.B.A. CEO of Caliper Life Sciences, and Dr. Paul Schoemaker, Ph.D. Chairman and CEO Decision Strategies International, Inc., The Wharton School.

For further information and registration, please visit:
http://bioconferencelive.com

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...